Clinical trials and animal experiments have demonstrated that both native GLP-1 and pharmacological GLP-1 receptor agonists (GLP-1 RAs) decrease the risk of cardiovascular events in individuals with T2DM (5, 6) through mechanisms such as reducing blood pressure, improving endothelial function and decreasing inflammation (7). The gene discussed is GCG; the disease is type 2 diabetes mellitus.